A Comparative Clinical Pharmacology Analysis of FDA‐Approved Targeted Covalent Inhibitors vs. Reversible Inhibitors in Oncology

药理学 临床药理学 医学 临床肿瘤学 内科学 癌症
作者
Huy Ngo,Yue Winnie Wen,Swathi Pisupati,Weize Huang,Sandhya Mandlekar
出处
期刊:Clinical Pharmacology & Therapeutics [Wiley]
卷期号:116 (5): 1198-1206 被引量:15
标识
DOI:10.1002/cpt.3390
摘要

Targeted covalent inhibitors (TCIs) are an emerging class of anticancer therapeutics. TCIs are designed to selectively engage their targeted proteins via covalent warheads. From the drug development standpoint, the covalent inhibition mechanism is anticipated to elicit the following theoretical benefits: (i) an extended duration of therapeutic action that is determined by the target protein turnover rate and not necessarily by drug half‐life, (ii) a lower therapeutic dose owing to greater pharmacological potency, (iii) lower risk of off‐target binding and associated adverse events, and (iv) reduced drug–drug interaction (DDI) liability due to high selectivity and low dose. Elucidating the clinical relevance of these expected benefits requires an integrated assessment of pharmacokinetics (PK), efficacy, safety, and DDI data. In this review, we compared the clinical pharmacology attributes of FDA‐approved oncology TCIs within the last 10 years against their reversible inhibitor (RI) counterparts. Our findings indicated that (i) PK half‐lives of TCIs were typically shorter and (ii) at their respective recommended clinical doses per drug label, the molar unbound steady state areas under the concentration‐time curve (AUC ss ) of TCIs were lower than those of RIs, but with longer clinically observed durations of response. However, (iii) there was no conclusive evidence supporting improved clinical safety profiles for TCIs, and (iv) DDI perpetrator profiles appeared to be similar between TCIs and RIs. The overall clinical pharmacology comparison of TCI vs. RI surveyed in this paper suggested that at least two of the four forecasted clinical benefits were achieved by TCIs.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
传奇3的应助被Jeremy采纳,获得30
刚刚
刚刚
刚刚
刚刚
1秒前
1秒前
muky发布了新的文献求助10
1秒前
Zhuyy完成签到,获得积分20
1秒前
1秒前
852的应助被波纹疾走打字机采纳,获得10
2秒前
2秒前
充电宝的应助被ldd采纳,获得10
2秒前
2秒前
图图耳朵发布了新的文献求助10
2秒前
春去春来发布了新的文献求助10
3秒前
4秒前
我爱学习完成签到,获得积分10
4秒前
Zuo发布了新的文献求助10
5秒前
顾矜的应助被Zhuyy采纳,获得10
5秒前
脑洞疼的应助被FZ采纳,获得10
5秒前
可爱的函函的应助被糖媛儿采纳,获得10
5秒前
5秒前
6秒前
李李李完成签到,获得积分10
6秒前
蟹寒樂发布了新的文献求助10
6秒前
趣生完成签到 ,获得积分10
7秒前
489关闭了489的文献求助
8秒前
科研小菜完成签到,获得积分10
8秒前
8秒前
caspar完成签到,获得积分10
8秒前
研友_VZG7GZ的应助被ku采纳,获得10
9秒前
科目三的应助被许可证采纳,获得10
9秒前
WWWWB发布了新的文献求助10
9秒前
xxv发布了新的文献求助10
10秒前
colourful完成签到,获得积分10
10秒前
深情安青的应助被can采纳,获得10
11秒前
典雅绮露完成签到,获得积分10
11秒前
烂漫时完成签到,获得积分10
11秒前
mate发布了新的文献求助10
11秒前
顾矜的应助被抠抠小手采纳,获得10
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183894
求助须知:如何正确求助?哪些是违规求助? 9573067
关于积分的说明 21829226
捐赠科研通 7780983
什么是DOI,文献DOI怎么找? 3434150
关于科研通互助平台的介绍 2558315
邀请新用户注册赠送积分活动 2480648